Journal ArticleOPEN ACCESS

Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea

  • Lee J
  • Kim J
  • Ahn J
  • et al.
Cancer Research and Treatment (2010) 42(1) 12
DOI: 10.4143/crt.2010.42.1.12
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.

Cite

CITATION STYLE

APA

Lee, J.-L., Kim, J. E., Ahn, J.-H., Lee, D.-H., Lee, J., Kim, C.-S., … Ahn, H. (2010). Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea. Cancer Research and Treatment, 42(1), 12. https://doi.org/10.4143/crt.2010.42.1.12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free